| Q52902527 | Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma. |
| Q39659810 | Beta1,4-galactosyltransferase V A growth regulator in glioma. |
| Q28295914 | Beta1,4-galactosyltransferase V functions as a positive growth regulator in glioma |
| Q38544783 | Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer |
| Q44894711 | Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm |
| Q48693039 | Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours |
| Q37314430 | Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells |
| Q36316506 | Functional interaction of E1AF and Sp1 in glioma invasion |
| Q87409486 | HMMC-1, a human monoclonal antibody to fucosylated core 1 O-glycan, suppresses growth of uterine endometrial cancer cells |
| Q89908242 | Heat Shock Cognate Protein 70 Enhanced Integrin β1 Mediated Invasion in Cancer Cells |
| Q33835228 | Identification of cell surface glycoprotein markers for glioblastoma-derived stem-like cells using a lectin microarray and LC-MS/MS approach |
| Q39639800 | Specificity of β1,4-galactosyltransferase inhibition by 2-naphthyl 2-butanamido-2-deoxy-1-thio-β-D-glucopyranoside |
| Q37615367 | The glycobiology of brain tumors: disease relevance and therapeutic potential |
| Q79151523 | UDP-Gal: GlcNAc-R beta1,4-galactosyltransferase--a target enzyme for drug design. Acceptor specificity and inhibition of the enzyme |
| Q47263168 | β1,4-Galactosyltransferase V activates Notch1 signaling in glioma stem-like cells and promotes their transdifferentiation into endothelial cells |
| Q92739724 | β4GALT1 controls β1 integrin function to govern thrombopoiesis and hematopoietic stem cell homeostasis |